BDBM338674 3-(trans-2-((cyclo- propylmethyl)amino)- cyclopropyl)-N-(1-(2,2,2- trifluoroethyl)piperidin- 4-yl)benzamide dihydrochloride::US9751885, 108::US9751885, 269::US9751885, 270::US9751885, 271

SMILES FC(F)(F)CN1CCC(CC1)NC(=O)c1cccc(c1)C1CC1NCC1CC1

InChI Key InChIKey=YCQZITFYDLFVFS-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 338674   

TargetLysine-specific histone demethylase 1A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 250nMAssay Description:A test compound dissolved in 2.5% DMSO was added by 4 μL to 3 μL reaction solution (50 mM Tris-HCl (pH 8.0), 0.1% BSA, 1 mM DTT) containing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetLysine-specific histone demethylase 1A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 290nMAssay Description:A test compound dissolved in 2.5% DMSO was added by 4 μL to 3 μL reaction solution (50 mM Tris-HCl (pH 8.0), 0.1% BSA, 1 mM DTT) containing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetLysine-specific histone demethylase 1A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 320nMAssay Description:A test compound dissolved in 2.5% DMSO was added by 4 μL to 3 μL reaction solution (50 mM Tris-HCl (pH 8.0), 0.1% BSA, 1 mM DTT) containing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetLysine-specific histone demethylase 1A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 870nMAssay Description:A test compound dissolved in 2.5% DMSO was added by 4 μL to 3 μL reaction solution (50 mM Tris-HCl (pH 8.0), 0.1% BSA, 1 mM DTT) containing...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 1.00E+4nMAssay Description:The MAO-B inhibitory activity evaluation described below followed the protocol of MAO-Glo (registered trademark) Assay of Promega KK.A test compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 1.00E+4nMAssay Description:The MAO-B inhibitory activity evaluation described below followed the protocol of MAO-Glo (registered trademark) Assay of Promega KK.A test compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 1.00E+4nMAssay Description:The MAO-B inhibitory activity evaluation described below followed the protocol of MAO-Glo (registered trademark) Assay of Promega KK.A test compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 1.00E+4nMAssay Description:A test compound dissolved in 4% DMSO was added by 12.5 μL to 25 μL reaction solution (100 mM HEPES (pH 7.5), 5% glycerol) containing 400 ng...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 1.00E+4nMAssay Description:A test compound dissolved in 4% DMSO was added by 12.5 μL to 25 μL reaction solution (100 mM HEPES (pH 7.5), 5% glycerol) containing 400 ng...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 1.00E+4nMAssay Description:A test compound dissolved in 4% DMSO was added by 12.5 μL to 25 μL reaction solution (100 mM HEPES (pH 7.5), 5% glycerol) containing 400 ng...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetAmine oxidase [flavin-containing] A(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 1.00E+4nMAssay Description:A test compound dissolved in 4% DMSO was added by 12.5 μL to 25 μL reaction solution (100 mM HEPES (pH 7.5), 5% glycerol) containing 400 ng...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent

TargetAmine oxidase [flavin-containing] B(Human)
Takeda Pharmaceutical

US Patent
LigandPNGBDBM338674(3-(trans-2-((cyclo- propylmethyl)amino)- cycloprop...)
Affinity DataIC50: 1.00E+4nMAssay Description:The MAO-B inhibitory activity evaluation described below followed the protocol of MAO-Glo (registered trademark) Assay of Promega KK.A test compound ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/11/2019
Entry Details
US Patent